1-(4-氟苯基)-2-(4-吡啶基)-1,2-乙烷二酮 | 152121-41-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氟苯基)-2-(4-吡啶基)-1,2-乙烷二酮
• 中文别名: 1-(4-氟苯基)-2-(4-吡啶基)-1,2-乙二酮
• 英文名称: 1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione
• 英文别名: 1-(4-fluorophenyl)-2-(pyridin-4-yl)ethan-1,2-dione；1-(4-fluorophenyl)-2-(4-pyridyl)-1,2-ethandione；1-(4-fluorophenyl)-2-(pyridin-4-yl)-1,2-ethandione；1-(4-fluorophenyl)-2-(4-pyridyl)ethanedione；1-(4-Fluorophenyl)-2-(4-pyridinyl)-1,2-ethanedione；1-(4-fluorophenyl)-2-pyridin-4-ylethane-1,2-dione
• CAS: 152121-41-0
• 化学式: C₁₃H₈FNO₂
• 分子量: 229.21
• InChiKey: PWXKRICWMZJIJO-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于丙酮、氯仿、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  | 室温 |

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)-2-(4-吡啶基)-1,2-乙烷二酮 生成 5-(4-fluoro-phenyl)-4-(4-pyridyl)-imidazole
  参考文献：
  名称：

  Substituted imidazoles useful in the treatment of inflammatory disease

  摘要：

  本发明涉及一系列取代咪唑的化合物，其化学式为I ##STR1## 包含它们的药物组成物以及用于制造它们的中间体。本发明的化合物抑制多种炎症细胞因子的产生，并可用于治疗与过度产生炎症细胞因子相关的疾病。

  公开号：

  US05965583A1
• 作为产物：
  描述：

  对氟苯甲酸乙酯 在 selenium(IV) oxide 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 1-(4-氟苯基)-2-(4-吡啶基)-1,2-乙烷二酮
  参考文献：
  名称：

  Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoccidial agents

  摘要：

  Several analogs of 2,3-diaryl pyrroles were synthesized and evaluated as inhibitors of Eimeria tenella cGMP-dependent protein kinase and in. in vivo anticoccidial assays. A 4-fluorophenyl group enhances both in vitro and in Vivo activities. The most potent analogs are the-5-(N-methyl, N-ethyl, and N-methylazetidine methyl) piperidyl derivatives 12, 23, and 34. These compounds have a broad spectrum of activity. Based on the in vivo efficacy and cost of synthesis, the N-ethyl analog 23 was chosen as a novel anticoccidial agent for a field trial. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.060

文献信息

• Imidazolyl-cyclic acetals
  申请人：Aventis Pharma Limited

  公开号：US06602877B1

  公开（公告）日：2003-08-05

  Compounds of formula (I) are described in which R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 is a group —L1—R7 or —L2—R8 [where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, —S(O)nR9, —NHSO2R9, —C(═Z)OR10, —C(═Z)R10, —OR10, —N(R11)—C(═Z)R9, —NY1Y2, —SO2NY1Y2, —C(═Z)—NY1Y2, —N(R11)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)R10, —C(═NOR10)R10, —C(═Z)NR10OR12, —N(R11)—C(═NR13)—NY1Y2 or —N(R11)—C(═Z)OR11; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl]; R4 is a group —L3—R14 [where L3 is a direct bond or an optionally substituted alkylene linkage and R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere), cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, nitro, —NY4Y5, —N(R10)—C(═Z)—R15; —N(R10)—C(═Z)—L4—R16, —NH—C(═Z)—NH—R15, —NH—C(═Z)—NH—L4—R16, —N(R10)—SO2—R15, —N(R10)—SO2—L4—R16, —S(O)nR9, —C(═Z)—NY4Y5 or —C(═Z)—OR9]; R5 is hydrogen, alkyl or hydroxyalkyl; or R4 and R5, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH2; R6 is hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals.

  式（I）的化合物描述如下：其中R1是可选择取代的杂环芳基；R2是可选择取代的芳基或可选择取代的杂环芳基；R3是一个基团—L1—R7或—L2—R8【其中L1是可选择取代的烷基链；R7是氢、芳基、氰基、环烷基、杂环芳基、杂环烷基、硝基、—S(O)nR9、—NHSO2R9、—C(═Z)OR10、—C(═Z)R10、—OR10、—N(R11)—C(═Z)R9、—NY1Y2、—SO2NY1Y2、—C(═Z)—NY1Y2、—N(R11)—C(═Z)—NY1Y2、—N(OR10)—C(═Z)—NY1Y2、—N(OR10)—C(═Z)R10、—C(═NOR10)R10、—C(═Z)NR10OR12、—N(R11)—C(═NR13)—NY1Y2或—N(R11)—C(═Z)OR11；L2是直接键或由2到约6个碳原子组成的直链或支链碳链，含有双键或三键碳-碳键；R8是氢、芳基、环烯基、环烷基、杂环芳基或杂环烷基】；R4是一个基团—L3—R14【其中L3是直接键或可选择取代的烷基链，R14是氢、烷基、叠氮基、羟基、烷氧基、芳基、芳基烷氧基、芳氧基、羧基（或酸生物等构异体）、环烷氧基、杂环芳基、杂环芳基烷氧基、杂环芳氧基、杂环烷基、杂环烷氧基、硝基、—NY4Y5、—N(R10)—C(═Z)—R15；—N(R10)—C(═Z)—L4—R16、—NH—C(═Z)—NH—R15、—NH—C(═Z)—NH—L4—R16、—N(R10)—SO2—R15、—N(R10)—SO2—L4—R16、—S(O)nR9、—C(═Z)—NY4Y5或—C(═Z)—OR9】；R5是氢、烷基或羟基烷基；或者R4和R5，当连接到同一碳原子时，可以与所述碳原子形成环烷基、环烯基或杂环烷基环或基团C═CH2；R6是氢或烷基；m为零或整数1或2；以及其N-氧化物，以及它们的前药；以及式（I）的化合物及其N-氧化物的药学上可接受的盐和溶剂（例如水合物），以及它们的前药。这些化合物是肿瘤坏死因子抑制剂，可用作药物。
• [EN] 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS<br/>[FR] INHIBITEURS DE LA CASÉINE KINASE 1 À BASE D'AZOLE 2,4,5-TRI-SUBSTITUÉ EN TANT QU'INDUCTEURS DE LA CARDIOMYOGENÈSE
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015119579A1

  公开（公告）日：2015-08-13

  This invention relates to a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof wherein R1, R2 and R3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl; X represents NR4, O or S; and R4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl. The method can be used in the late phase of stem cell differentiation and in the compounds of formula (I) or (II) in combination with other small molecules can lead to especially high differentiation of stem cells into cardiomyocytes. The invention further relates to novel compounds which can be used in the method of the invention and kits for stem cell differentiation.

  本发明涉及一种通过酪蛋白激酶1抑制诱导或增强多能干细胞向心肌细胞分化的方法，所述方法包括将干细胞培养在含有式(I)或(II)的酪蛋白激酶1抑制剂的培养基中，或其立体异构体、互变异构体或盐中，其中R1、R2和R3独立地表示氢、可选择地取代的烷基、烯烃基、炔烃基、杂环基、杂芳基或芳基；X表示NR4、O或S；R4表示氢、可选择地取代的烷基、烯烃基、炔烃基、杂环基、杂芳基或芳基。该方法可用于干细胞分化的后期阶段，结合式(I)或(II)的化合物与其他小分子一起可导致干细胞特别高效地分化为心肌细胞。该发明还涉及可用于该方法的新化合物以及用于干细胞分化的试剂盒。
• [EN] SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] IMIDAZOLES SUBSTITUES UTILISABLES DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ORTHO-MCNEIL CORPORATION, INC.

  公开号：WO1998047892A1

  公开（公告）日：1998-10-29

  (EN) This invention relates to a series of substituted imidazoles of Formula (I), pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention inhibit the production of a number of inflammatory cytokines, and are useful in the treatment of diseases associated with overproduction of inflammatory cytokines.(FR) L'invention a pour objet une série d'imidazoles substitués ayant la formule (I), des compositions pharmaceutiques comprenant ces imidazoles et des intermédiaires utilisés dans leur fabrication. Les composés faisant l'objet de cette invention inhibent la production de plusieurs cytokines inflammatoires et peuvent s'utiliser pour traiter des maladies liés à une surproduction de cytokines inflammatoires.

  该发明涉及一系列具有式(I)的取代咪唑，包括含有它们的制药组合物和用于制造它们的中间体。该发明的化合物抑制多种炎性细胞因子的产生，可用于治疗与炎性细胞因子过度产生相关的疾病。
• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1993014081A1

  公开（公告）日：1993-07-22

  (EN) Novel 2,4,5-triarylimidazole compounds and compositions for use in therapy.(FR) Nouveaux composés 2,4,5-triarylimidazole et compositions s'utilisant en thérapie.

  (EN) 新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合物。 (FR) 新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合物。
• Novel compounds
  申请人：SmithKline Beecham Corporation

  公开号：US20030064997A1

  公开（公告）日：2003-04-03

  Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

  小说2,4,5-三芳基咪唑化合物及其在治疗中的应用组成物。